| Tesamorelin Basic information |
| Product Name: | Unii-mqg94m5eeo |
| Synonyms: | Tesamorelin;Th 9507;Th-9507;Unii-mqg94m5eeo;High Pure Peptides Th9507 Tesamorelin Powder 2mg/Vial |
| CAS: | 804475-66-9 |
| MF: | C221H366N72O67S |
| MW: | 5135.77794 |
| EINECS: | 200-048-4 |
| Mol File: | 804475-66-9.mol |
 |
|
| Unii-mqg94m5eeo Usage And Synthesis |
| Description | In the pituitary, GH is secreted in a pulsatile manner. GH control is regulated by somatostatin and the negative feedback regulator, IGF-1. Direct administration of GH to patients with lipodystrophy decreases VAT but has associated side effects such as fluid retention and joint swelling. Because of the side effects associated with direct GH administration, GHRH represents a attractive mechanism for increasing GH levels. Tesomorelin is an analog of GHRH in which the N-terminal amino acid, Tyr, is amidated with a trans-3-hexenoyl group. Capping of the N-terminus protects GHRH from cleavage by DPP-4. Tesomorelin demonstrates enhanced stability compared with GHRH in animal models. |
| ues | Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. |
